Gan & Lee Pharmaceuticals
SSE:603087
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.1
59.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gan & Lee Pharmaceuticals
Gan & Lee Pharmaceuticals
Income from Continuing Operations
Gan & Lee Pharmaceuticals
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gan & Lee Pharmaceuticals
SSE:603087
|
Income from Continuing Operations
¥340.2m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Income from Continuing Operations
-¥6.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Income from Continuing Operations
¥1.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Income from Continuing Operations
¥1.2B
|
CAGR 3-Years
22%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Income from Continuing Operations
¥1.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Income from Continuing Operations
¥3.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
12%
|
CAGR 10-Years
39%
|
|
Gan & Lee Pharmaceuticals
Glance View
Gan & Lee Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of recombinant insulin analogue raw materials and injections. The company is headquartered in Beijing, Beijing and currently employs 3,278 full-time employees. The company went IPO on 2020-06-29. The firm's main products are insulin preparations and insulin dry powder, including Changxiulin recombinant insulin glargine injection and Suxiulin recombinant insulin lispro injection. The company is also involved in the development and sales of a type of insulin pen called Xiulin Pen and the components. The firm provides early-stage franchising services by authorizing other companies to sell its insulin injections. The firm sells its products to both domestic and international markets, including Mexico and the Middle East.
See Also
What is Gan & Lee Pharmaceuticals's Income from Continuing Operations?
Income from Continuing Operations
340.2m
CNY
Based on the financial report for Dec 31, 2023, Gan & Lee Pharmaceuticals's Income from Continuing Operations amounts to 340.2m CNY.
What is Gan & Lee Pharmaceuticals's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-18%
The average annual Income from Continuing Operations growth rates for Gan & Lee Pharmaceuticals have been -35% over the past three years , -18% over the past five years .
You don't have any saved screeners yet
